Genzyme

• High Hopes and Altered Genes

  By Kenneth Silber  |  October 1, 2009

  Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...

• Soapbox: Algorithms vs. Arithmetic

  By Contributing Writer  |  June 1, 2009

  There are security analysts and financial advisors who have no fear about taking positions in derivatives based on arcane algorithms. But for some reason, these...

• Interview: Tony Weber and Chuck McCurdy of ABN AMRO Veredus Select Growth Fund

  By Staff Writer  |  September 30, 2005

  S&P Rank: 5 Stars Using Inefficiency to Their Advantage

• Domestic Equity Funds -- July 2003 Review

  By Staff Writer  |  August 11, 2003

  'Rising Tide Lifts All Boats'

• Evan McCulloch of Franklin Biotechnology Discovery

  By Staff Writer  |  February 10, 2003

  S&P Rank: 3 Stars Strong Dose of Biotech